[go: up one dir, main page]

DK0797987T3 - Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf - Google Patents

Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf

Info

Publication number
DK0797987T3
DK0797987T3 DK95940461T DK95940461T DK0797987T3 DK 0797987 T3 DK0797987 T3 DK 0797987T3 DK 95940461 T DK95940461 T DK 95940461T DK 95940461 T DK95940461 T DK 95940461T DK 0797987 T3 DK0797987 T3 DK 0797987T3
Authority
DK
Denmark
Prior art keywords
preparation
sustained
release
granular preparations
release granular
Prior art date
Application number
DK95940461T
Other languages
Danish (da)
English (en)
Inventor
Hiroaki
Masazumi
Shinji
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of DK0797987T3 publication Critical patent/DK0797987T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK95940461T 1994-12-19 1995-12-18 Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf DK0797987T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31441494 1994-12-19
PCT/JP1995/002594 WO1996019200A1 (fr) 1994-12-19 1995-12-18 Preparation granulaire a liberation prolongee et procede de production

Publications (1)

Publication Number Publication Date
DK0797987T3 true DK0797987T3 (da) 2004-02-16

Family

ID=18053063

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940461T DK0797987T3 (da) 1994-12-19 1995-12-18 Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf

Country Status (14)

Country Link
US (2) US5858411A (fr)
EP (1) EP0797987B1 (fr)
JP (1) JP3893439B2 (fr)
KR (1) KR100424931B1 (fr)
CN (1) CN1093758C (fr)
AT (1) ATE251896T1 (fr)
DE (1) DE69531957T2 (fr)
DK (1) DK0797987T3 (fr)
ES (1) ES2210321T3 (fr)
FI (1) FI119720B (fr)
NO (1) NO320356B1 (fr)
PT (1) PT797987E (fr)
TW (1) TW406022B (fr)
WO (1) WO1996019200A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6632455B2 (en) * 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
ATE254908T1 (de) 1998-09-30 2003-12-15 Basf Ag Verwendung von wasserlöslichen oder wasserdispergierbaren polyether-haltigen pfropfpolymerisaten als überzugsmittel, bindemittel und/oder filmbildender hilfsstoff in pharmazeutischen darreichungsformen
EP1027885B1 (fr) * 1999-02-09 2008-07-09 Pfizer Products Inc. Compositions de médicaments basiques avec une meilleure biodisponibilité
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
GB0003782D0 (en) * 2000-02-17 2000-04-05 Dumex Ltd As Process
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
WO2006023000A1 (fr) * 2004-07-30 2006-03-02 Xanodyne Pharmaceuticals, Inc. Formules d’acide tranéxamique
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20070082048A1 (en) * 2005-06-08 2007-04-12 Ronald Warner Sleep aid formulations
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
HRP20141001T1 (hr) * 2006-03-16 2014-12-05 Euro-Celtique S.A. Farmaceutski sferoidi
MX2008010233A (es) * 2008-03-10 2009-11-10 Eurodrug Lab B V Composicion de liberacion modificada, que comprende doxofilina.
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011091164A1 (fr) * 2010-01-22 2011-07-28 Xenoport, Inc. Formes galéniques orales ayant une charge élevée d'un promédicament d'acide tranexamique
WO2011102505A1 (fr) * 2010-02-22 2011-08-25 第一三共株式会社 Préparation solide à libération prolongée pour usage oral
GB201010083D0 (en) * 2010-06-16 2010-07-21 Univ Bradford Compositions and methods
KR102286952B1 (ko) * 2013-12-31 2021-08-09 롯데정밀화학 주식회사 입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말
EP3340982B1 (fr) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AU2017290593A1 (en) 2016-06-27 2019-01-03 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2020041301A1 (fr) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020081723A1 (fr) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux
WO2021127452A1 (fr) 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Composés pour le traitement d'infections bactériennes et la potentialisation d'antibiotiques
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330338A (en) * 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4329451A (en) * 1980-11-03 1982-05-11 The Dow Chemical Company Preparing an aqueous dispersion of colloidal size particles of a water-insoluble polysaccharide derivative
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
CA1334379C (fr) * 1987-11-24 1995-02-14 James William Mcginity Methode de preparation d'une composition active a liberation prolongee
US5051261A (en) * 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
US4835188A (en) * 1987-12-08 1989-05-30 American Home Products Corporation Spray dried ibuprofen
US4916161A (en) * 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
EP0421582A1 (fr) * 1989-10-03 1991-04-10 Warner-Lambert Company Microcapsules sphéroidales sechées par pulvérisation masticables et microcapsules revêtues par un polymère et méthodes pour leur préparation
JPH03232814A (ja) * 1990-02-08 1991-10-16 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
JP2915590B2 (ja) * 1991-02-15 1999-07-05 第一製薬株式会社 マスクされた粒状物
JP2527107B2 (ja) * 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
DE4244466C2 (de) * 1992-12-24 1995-02-23 Pharmatech Gmbh Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten

Also Published As

Publication number Publication date
KR100424931B1 (ko) 2004-07-05
CN1093758C (zh) 2002-11-06
PT797987E (pt) 2004-02-27
JP3893439B2 (ja) 2007-03-14
US6030644A (en) 2000-02-29
DE69531957D1 (de) 2003-11-20
TW406022B (en) 2000-09-21
NO320356B1 (no) 2005-11-28
FI119720B (fi) 2009-02-27
EP0797987B1 (fr) 2003-10-15
EP0797987A1 (fr) 1997-10-01
DE69531957T2 (de) 2004-08-12
NO972814L (no) 1997-08-18
WO1996019200A1 (fr) 1996-06-27
US5858411A (en) 1999-01-12
NO972814D0 (no) 1997-06-18
FI972622L (fi) 1997-06-18
ES2210321T3 (es) 2004-07-01
ATE251896T1 (de) 2003-11-15
CN1170357A (zh) 1998-01-14
EP0797987A4 (fr) 1998-09-09
FI972622A0 (fi) 1997-06-18

Similar Documents

Publication Publication Date Title
DK0797987T3 (da) Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf
NZ239802A (en) A superior tasting pharmaceutical composition having porous particles produced through in situ gas generation and a process for its production
NO944473D0 (no) Sammensetninger med vedvarende frigjöring og fremgangsmåte for fremstilling av farmasöytiske sammensetninger
MY109813A (en) Process of preparing large dimension emulsion polymer particles, polymer product and uses thereof
HUT59000A (en) Process for producing pharmaceutical preparations containing 4-phenyl-1,2,3,4-tetrahydro-1-naphtalinamine-derivatives
CA2229266A1 (fr) Procedes et compositions applicables aux chlorures de polyaluminium et aux chlorosulfates de polyaluminium
HUT59005A (en) Process for producing transdermal pharmaceutical preparations containing 2-amino-6-(propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
FR2627773B1 (fr) Particules fines de polyorganosilsesquioxane et procede de production de ces particules
DE59305700D1 (de) Verfahren zur Herstellung von festen pharmazeutischen Retardformen
TW270085B (fr)
RU93051352A (ru) Замещенные производные циклогексана, способ их получения и применение соединений для лечения заболеваний
ATE230987T1 (de) Pranlukast enthaltende granula, verfahren zur herstellung der granula und verfahren zur verminderung des zusammenbackens von pranlukast
CA2017851A1 (fr) Particules biodegradables micronisees; methode de preparation et utilisation
EP0606930A3 (en) Process for preparation of polymer particles, process for preparation of toner particles and particles prepared according to these processes.
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
JPS6456699A (en) Method for obtaining alpha 1-antitrypsin concentrate from human plasma and its utilization as drug
CA2207334A1 (fr) Preparations granulaires a liberation prolongee et procede pour leur production
FR2689876B1 (fr) Dispersions silico-acryliques, leur procédé d'obtention, leur application en stéréophotolithographie et procédé de préparation d'objets en résine.
HUT60509A (en) Process for producing monomer and 125 i-marked derivatives of t-butyloxycarbonyl-l-tyrosylpeptidoglycan
EP0480391A3 (en) Emulsion-free emulsion polymers, their production and their use in sustained-release pharmaceutical compositions
MY105082A (en) Separation process
NO882255L (no) Fremgangsmaate for fremstilling av olefin-maleinsyreanhydrid-kopolymer i form av partikler.
CS39189A2 (en) Method of tetrahydropyridine derivatives production
ZA200006695B (en) Granulator organosilane preparation, process for the production thereof and use thereof.
HK2794A (en) 8a-acylaminoergoline, its preparation and pharmaceutical compositions containing it